Technical Scrutiny: GlaxoSmithKline PLC, Keryx Biopharma Inc., AstraZeneca PLC, and Raptor Pharma Corp.

LONDON, September 19, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Wednesday, September 18, 2013, the Dow Jones Industrial Average, the S&P 500 and the NASDAQ Composite finished the day 0.95%, 1.22% and 1.01% higher, respectively. Shares in the major drug manufacturer companies ended mostly on a higher note as the broader market posted gains. The major movers included GlaxoSmithKline PLC (NYSE: GSK), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), AstraZeneca PLC (NYSE: AZN), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). AAAResearchReports.com has tracked GSK, KERX, AZN, and RPTP. These reports can be seen for free at:

http://www.aaaresearchreports.com/register/  

On Wednesday, GlaxoSmithKline PLC's stock advanced to close at $51.27, up 0.27% from the previous day's closing price of $51.13. The company's shares oscillated between $50.53 and $51.40 during the trading session. A total of 2.41 million shares were traded, which is above the daily average volume of 2.08 million. The company's shares have lost 0.27% in the previous three trading sessions, compared to a gain of 2.22% in the S&P 500 during the same period. Further, GlaxoSmithKline PLC's stock is trading above its 200-day moving average of $48.53. Download free research on GSK by signing up now at:

http://www.AAAResearchReports.com/GSK091913.pdf

Shares in Keryx Biopharmaceuticals Inc. fell sharply on Wednesday, even as the broader market posted significant gains. The company's shares fluctuated between $9.56 and $9.93 before closing the day 1.00% lower at $9.90. A total of 2.94 million shares were traded, which is more than the daily average volume of 1.92 million. Despite Wednesday's pullback, the company's shares have rallied 18.14% in the previous one month and 29.24% in the last three months, outperforming the S&P 500 which has gained 4.21% and 4.46% during the respective periods.  Moreover, Keryx Biopharmaceuticals Inc.'s stock has moved closer to its 52-week high of $10.04 as well as above its 50-day and 200-day moving averages of $8.82 and $6.97, respectively. Register for today's free analysis on KERX at:

http://www.AAAResearchReports.com/KERX091913.pdf

On Wednesday, AstraZeneca PLC's shares rose sharply by 1.58%, tracking gains in the US equity market. The company's shares finished the day at $52.08 after fluctuating between $51.22 and $52.13 during the trading session. A total of 1.36 million shares were traded, which is below the daily average volume of 1.68 million. The company's stock has gained 2.82% in the previous three trading sessions and 4.18% in the last one month, outperforming the S&P 500 which has gained 2.22% and 4.21% during the respective periods. Additionally, AstraZeneca PLC's shares are trading above their 50-day 200-day moving averages of $50.16 and $49.27, respectively. A free report on AZN can be accessed by registering at:

http://www.AAAResearchReports.com/AZN091913.pdf

Shares in Raptor Pharmaceutical Corp. edged higher on Wednesday, extending the gains from the previous trading session. The company's shares finished the day 0.35% higher at $14.35 after fluctuating between $14.04 and $14.42 during the trading session. A total of 0.60 million shares were traded, which is below the daily average volume of 0.72 million. The company's shares have rallied 83.27% in the previous three months and 25.88% in the last one month, outperforming the S&P 500 which has advanced 4.46% and 4.21% during the respective periods. Further, Raptor Pharmaceutical Corp.'s stock is trading close to its 52-week high of $14.90 as well as above its 50-day and 200-day moving averages of $11.80 and $7.57, respectively. Register with AAA Research Reports and download research on RPTP for free at:

http://www.AAAResearchReports.com/RPTP091913.pdf

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AAAresearchreports.com

SOURCE AAA Research Reports